Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial

Open access
DE JAGER, J., KOOY, A., LEHERT, Ph., BETS, D., WULFFELÉ, M. G., TEERLINK, T., SCHEFFER, P. G., SCHALKWIJK, C. G., DONKER, A. J. M., STEHOUWER, C. D. A.·2005·Journal of Internal Medicine

Abstract

Abstract.: Objectives. The UK Prospective Diabetes Study (UKPDS) showed that treatment with metformin decreases macrovascular morbidity and mortality independent of glycaemic control. We hypothesized that metformin may achieve this by improving endothelial function and chronic, low‐grade inflammation. Data on this issue are scarce and we therefore tested, in the setting of a randomized, placebo‐controlled trial, whether metformin can affect endothelial function and low‐grade inflammation. Design. The Hyperinsulinaemia the Outcome of its Metabolic Effects (HOME) trial is a double‐blind trial, in which all patients were randomized to receive either metformin or placebo in addition to insulin therapy. At the beginning and the end of a 16‐week treatment period fasting blood samples were drawn and a physical examination was carried out. Setting. The trial was conducted in the outpatient clinics of three nonacademic hospitals (Hoogeveen, Meppel and Coevorden; the Netherlands). Subjects. Patients were included if they were between 30 and 80 years of age; had received a diagnosis of diabetes after the age of 25; had never had an episode of ketoacidosis; and their blood glucose‐lowering treatment previously consisted of oral agents but now only consisted of either insulin (n = 345) or insulin and metformin (n = 45). We excluded pregnant women and women trying to become pregnant, patients with a Cockroft‐Gault‐estimated creatinine clearance <50 mL min−1, or low plasma cholinesterase (reference value <3.5 units L−1), patients with congestive heart failure (New York Heart Association class III/IV), or patients with other serious medical or psychiatric disease. A total of 745 eligible patients were approached; 390 gave informed consent and were randomized (196 metformin, 194 placebo). About 353 patients completed 16 weeks of treatment (171 metformin, 182 placebo). Main outcome measures. The HOME trial was designed to study the metabolic and cardiovascular effects of metformin during a follow‐up of 4 years. Presented here are the results of an interim analysis after 16 weeks of treatment. Results. When compared with placebo, metformin treatment was associated with an increase in urinary albumin excretion of 21% (−1 to +48; P = 0.06); a decrease in plasma von Willebrand factor of 6% (−10 to −2; P = 0.0007); a decrease in soluble vascular cell adhesion molecule‐1 of 4% (−7 to −2; P = 0.0002); a decrease in soluble E‐selectin of 6% (−10 to −2; P = 0.008); a decrease in tissue‐type plasminogen activator of 16% (−20 to −12; P < 0.0001); and a decrease in plasminogen activator inhibitor‐1 of 20% (−27 to −10; P = 0.0001). These changes could not be explained by metformin‐associated changes in glycaemic control, body weight or insulin dose. Markers of inflammation, i.e. C‐reactive protein and soluble intercellular adhesion molecule‐1, did not change with metformin treatment. Conclusions. In patients with type 2 diabetes treated with insulin, metformin treatment was associated with improvement of endothelial function, which was largely unrelated to changes in glycaemic control, but not with improvement of chronic, low‐grade inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2004.01420.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 45

  1. 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  2. 10.1056/NEJM199901143400207 · DOI · Paper page
  3. 10.2337/diabetes.51.4.1157 · DOI · Paper page
  4. 10.2337/diabetes.49.3.485 · DOI · Paper page
  5. 10.2337/diacare.16.4.621 · DOI · Paper page
  6. 10.2337/diacare.19.1.64 · DOI · Paper page
  7. 10.1046/j.1365-2362.1999.00497.x · DOI
  8. 10.2337/diacare.25.12.2133 · DOI · Paper page
  9. 10.1159/000180580 · DOI · Paper page
  10. 10.1016/0009-8981(95)06067-N · DOI
  11. 10.1046/j.1365-2796.2003.01213.x · DOI · Paper page
  12. Passing H, 1984, Comparison of several regression procedures for method comparison studies and determination of sample sizes: II. Application of linear regression procedures for method comparison studies in clinical chemistry, J Clin Chem Clin Biochem, 22, 431
  13. 10.1093/clinchem/43.10.1904 · DOI
  14. Scheffer PG, 1998, Measurement of LDL particle size in whole plasma and serum by high performance gel‐filtration chromatography using a fluorescent lipid probe, Clin Chem, 44, 2148, 10.1093/clinchem/44.10.2148 · DOI
  15. 10.1016/S0008-6363(96)00272-6 · DOI · Paper page
  16. 10.1161/01.ATV.18.9.1359 · DOI · Paper page
  17. Vapaatalo H, 2001, Clinically important factors influencing endothelial function, Med Sci Monit, 7, 1075
  18. 10.1161/hh2101.099270 · DOI · Paper page
  19. 10.1111/j.1464-5491.1991.tb01610.x · DOI
  20. 10.2337/diacare.25.12.2123 · DOI
  21. 10.1046/j.1464-5491.1999.00201.x · DOI
  22. 10.2337/diacare.21.6.1008 · DOI
  23. 10.2337/diacare.24.3.549 · DOI
  24. 10.1161/01.ATV.18.5.723 · DOI · Paper page
  25. 10.1161/hc4401.098490 · DOI · Paper page
  26. 10.1055/s-0037-1615401 · DOI
  27. 10.2337/diacare.21.12.2135 · DOI · Paper page
  28. 10.7326/0003-4819-130-5-199903020-00002 · DOI · Paper page
  29. 10.1016/S0188-4409(00)00241-1 · DOI
  30. 10.1007/BF00285287 · DOI · Paper page
  31. 10.1210/jc.2002-021688 · DOI · Paper page
  32. 10.1089/15209150050025230 · DOI
  33. 10.1016/S1262-3636(03)72796-7 · DOI
  34. 10.2337/diabetes.48.1.198 · DOI · Paper page
  35. 10.1016/S0006-2952(99)00263-4 · DOI · Paper page
  36. 10.1016/S0014-2999(99)00342-8 · DOI
  37. 10.2337/diacare.20.12.1863 · DOI
  38. 10.1210/jc.74.5.1020 · doi:10.1210/jc.74.5.1020
  39. 10.1016/S0006-291X(02)02464-6 · DOI
  40. 10.1053/meta.2002.31332 · DOI
  41. 10.1053/meta.2001.28078 · DOI · Paper page
  42. 10.2337/diabetes.52.3.667 · DOI · Paper page
  43. 10.1210/jc.2002-021193 · DOI
  44. 10.1055/s-2007-978682 · DOI
  45. 10.1055/s-2007-979059 · DOI

Cited by

See all 220

Metadata

Authors
DE JAGER, J., KOOY, A., LEHERT, P., BETS, D., WULFFELÉ, M. G., TEERLINK, T., SCHEFFER, P. G., SCHALKWIJK, C. G., DONKER, A. J. M., & STEHOUWER, C. D. A.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2004-12-07
Volume
257
Issue
1
Pages
100-109
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W1995897557
Cited by
220
References
5
FWCI
7.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1365-2796.2004.01420.x
The paper
DE JAGER, J., KOOY, A., LEHERT, P., BETS, D., WULFFELÉ, M. G., TEERLINK, T., SCHEFFER, P. G., SCHALKWIJK, C. G., DONKER, A. J. M., & STEHOUWER, C. D. A. (2005). Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2004.01420.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.